Home › Trial NCT06266091
Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody
- Trial IDNCT06266091
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorWuhan YZY Biopharma Co., Ltd.
- Enrollment115
- Start date2021-11-24
- ConditionsMalignant Ascites
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.